DK0815245T3 - Bioaktive IL 12 fusionsproteiner - Google Patents

Bioaktive IL 12 fusionsproteiner

Info

Publication number
DK0815245T3
DK0815245T3 DK96905439T DK96905439T DK0815245T3 DK 0815245 T3 DK0815245 T3 DK 0815245T3 DK 96905439 T DK96905439 T DK 96905439T DK 96905439 T DK96905439 T DK 96905439T DK 0815245 T3 DK0815245 T3 DK 0815245T3
Authority
DK
Denmark
Prior art keywords
bioactive
fusion proteins
polypeptide
chains
joined
Prior art date
Application number
DK96905439T
Other languages
Danish (da)
English (en)
Inventor
Richard C Mulligan
Graham J Lieschke
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of DK0815245T3 publication Critical patent/DK0815245T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96905439T 1995-02-08 1996-02-07 Bioaktive IL 12 fusionsproteiner DK0815245T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/385,335 US5891680A (en) 1995-02-08 1995-02-08 Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
PCT/US1996/001787 WO1996024676A1 (en) 1995-02-08 1996-02-07 Bioactive fusion proteins and pre-existing tumor therapy

Publications (1)

Publication Number Publication Date
DK0815245T3 true DK0815245T3 (da) 2008-07-21

Family

ID=23520989

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96905439T DK0815245T3 (da) 1995-02-08 1996-02-07 Bioaktive IL 12 fusionsproteiner

Country Status (11)

Country Link
US (1) US5891680A (es)
EP (1) EP0815245B1 (es)
JP (2) JP3919220B2 (es)
AT (1) ATE391181T1 (es)
AU (1) AU701918B2 (es)
DE (1) DE69637480T2 (es)
DK (1) DK0815245T3 (es)
ES (1) ES2302565T3 (es)
MX (1) MX9706050A (es)
PT (1) PT815245E (es)
WO (1) WO1996024676A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213512A1 (en) * 1995-12-22 1997-07-03 Toray Industries, Inc. Method for producing bioactive fusion protein
AU4401297A (en) * 1996-09-21 1998-04-14 Viromedica Pacific Limited Improved retroviral vectors for gene therapy
JP2001503258A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド 遺伝子発現および搬送系および用途
WO1998017689A2 (en) * 1996-10-18 1998-04-30 Valentis Inc. Il-12 gene expression and delivery systems and uses
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
CA2265505C (en) * 1997-05-16 2009-09-08 Toray Industries, Inc. An immune disease remedy, treatment method and preventive agent and method for dogs and cats
ZA986596B (en) * 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ATE329622T1 (de) * 1998-04-15 2006-07-15 Lexigen Pharm Corp Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
CA2343156A1 (en) * 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
DE19919148A1 (de) * 1999-04-27 2000-11-16 Wieser Raimund J Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere
AU6094100A (en) * 1999-07-13 2001-01-30 Heska Corporation Fc epsilon receptor-luminescence inducing protein chimeric nucleic acid molecules, fusion proteins and uses thereof
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU778611B2 (en) * 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
EP1731531B1 (en) 1999-08-09 2012-05-30 Merck Patent GmbH Multiple cytokine-antibody complexes
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP3184637A1 (en) 1999-09-09 2017-06-28 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30 complexes, antibodies, uses in pharmaceutical compositions
WO2001025277A1 (en) * 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
ATE336514T1 (de) * 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
JP5390055B2 (ja) * 2000-06-29 2014-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
ES2393733T3 (es) * 2001-03-07 2012-12-27 Merck Patent Gmbh Tecnología de expresión para proteínas que contienen una fracción de anticuerpo de isotipo híbrido
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
RU2306320C9 (ru) * 2001-05-03 2008-01-27 Мерк Патент Гмбх Рекомбинантное опухолеспецифичное антитело (варианты) и его применение
CN100390282C (zh) * 2001-12-04 2008-05-28 默克专利有限公司 具有调节的选择性的il-2融合蛋白
US20030235548A1 (en) * 2002-06-12 2003-12-25 L'oreal Cosmetic composition for care and/or treatment and/or makeup of the emulsion type structured with silicone polymers
US7169904B2 (en) * 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
EP1702069A2 (en) * 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
EA016022B1 (ru) 2004-12-21 2012-01-30 Сентокор, Инк. Выделенное антитело млекопитающего против il-12 и способ изменения его активности
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US9387242B2 (en) 2005-12-02 2016-07-12 Icahn School Of Medicine At Mount Sinai Chimeric viruses presenting non-native surface proteins and uses thereof
JP5175214B2 (ja) 2005-12-30 2013-04-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 改良された安定性を有するインターロイキン−１２ｐ４０変種
US20120225933A1 (en) 2009-11-05 2012-09-06 Gonzalez Aseguinolaza Gloria Regulated expression systems
AU2014241843B2 (en) 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
AU2014262469B2 (en) 2013-05-10 2019-11-14 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
KR102407019B1 (ko) 2014-02-27 2022-06-08 머크 샤프 앤드 돔 코포레이션 암의 치료를 위한 결합 방법
JP2018537432A (ja) 2015-11-09 2018-12-20 イミューン デザイン コーポレイション Ｉｌ−１２を発現するレンチウイルスベクターを含む組成物およびその使用法
BR112018069776A2 (pt) 2016-03-29 2019-02-05 Janssen Biotech Inc tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
RS63912B1 (sr) 2016-05-18 2023-02-28 Modernatx Inc Polinukleotidi koji kodiraju interleukin-12 (il12) i njihove upotrebe
EP3523323A4 (en) * 2016-10-07 2020-06-17 Board of Regents, The University of Texas System T-CELLS WITH EXPRESSION OF MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER
AU2018231170B2 (en) 2017-03-06 2020-07-16 Altor Bioscience Corporation IL-15-based fusions to IL-12 and IL-18
CN108686202A (zh) 2017-04-06 2018-10-23 张晋宇 肿瘤免疫疗法
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
EP3630156A4 (en) * 2017-05-25 2021-03-31 The Broad Institute, Inc. LYMPHOCYTARY ANTIGEN, CD5-LIKE (CD5L) MONOMERS, HOMODIMERS, AND INTERLEUKINE 12B (P40) HETERODIMERS AGONISTS AND METHODS OF USE THEREOF
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
CN109796534B (zh) * 2017-11-16 2021-08-10 北京比洋生物技术有限公司 抗il-17抗体/tnfr ecd融合蛋白及其用途
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
CA3160103A1 (en) 2018-09-24 2020-04-02 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
KR102524247B1 (ko) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
CN111848810A (zh) * 2019-04-28 2020-10-30 张晋宇 一种蛋白质分子及其用途
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
WO2020255010A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
CN112210014B (zh) * 2019-07-12 2022-10-11 北京科诺科服生物科技有限公司 一种用于治疗动物肿瘤的融合蛋白及组合物
KR20240015030A (ko) * 2022-07-25 2024-02-02 충남대학교산학협력단 E5의 분비를 위한 재조합 발현 벡터 및 이로 형질전환된약독화 살모넬라 균주

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082658A (en) * 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JP2893653B2 (ja) * 1988-11-10 1999-05-24 ジェネティックス・インスティテュート・インコーポレイテッド ナチュラルキラー細胞刺激因子
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
DK0790308T3 (da) * 1989-12-22 2007-10-08 Hoffmann La Roche Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
CA2074825C (en) * 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
ES2257734T3 (es) * 1992-05-18 2006-08-01 Genentech, Inc. Activacion de los receptores de oligomerizacion por medio de los ligandos de receptores fusionados.
JP3312357B2 (ja) * 1992-12-11 2002-08-05 ザ ダウ ケミカル カンパニー 多価の一本鎖抗体
IT1270866B (it) * 1993-03-10 1997-05-13 Eniricerche Spa Vettore ricombinante e suo impiego per la preparazione esocellulare di anticorpi in forma di singola molecola da bacillus subtilis
ZA942206B (en) * 1993-04-01 1994-10-31 Amgen Inc Biologically active polypeptide fusion dimers
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
CH687795C1 (fr) * 1994-05-07 2001-05-15 Omega Sa Piece d'horlogerie mecanique pourvue d'un tourbillon.
US5650490A (en) * 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2

Also Published As

Publication number Publication date
US5891680A (en) 1999-04-06
EP0815245A1 (en) 1998-01-07
MX9706050A (es) 1997-11-29
PT815245E (pt) 2008-07-09
DE69637480T2 (de) 2009-04-09
JP2006314332A (ja) 2006-11-24
WO1996024676A1 (en) 1996-08-15
ES2302565T3 (es) 2008-07-16
ATE391181T1 (de) 2008-04-15
EP0815245B1 (en) 2008-04-02
AU4919896A (en) 1996-08-27
JPH10513362A (ja) 1998-12-22
AU701918B2 (en) 1999-02-11
JP3919220B2 (ja) 2007-05-23
DE69637480D1 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
DK0815245T3 (da) Bioaktive IL 12 fusionsproteiner
EP1304382A3 (en) Production of peptides in plants as viral coat protein fusions
DE3856265D1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
NZ236819A (en) Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
DE69738586D1 (de) Hohe expressionsrate von proteinen
WO1997028247A3 (fr) PROTEINES DE RESERVE DE PLANTES ENRICHIES EN ACIDES AMINES, NOTAMMENT η-ZEINE DE MAIS ENRICHIE EN LYSINE, PLANTES EXPRIMANT CES PROTEINES
ES2100960T3 (es) Estructura proteica de la toxina vegetal gelonina.
NO911557D0 (no) Fremgangsmaate for fremstilling av fremmedproteiner i streptomyceter.
DK0467839T3 (da) In-vitro-behandling af fusionsproteiner
ATE143974T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
AU637589B2 (en) Ancrod proteins, their production and use
DE69623803D1 (de) Verwendung von KASEINFRAGMENTEn als WACHSTUMERFÖRDERer